Gain Therapeutics Inc (GANX) — Cash Flow-to-Debt Ratio
Gain Therapeutics Inc (GANX) has a Cash Flow-to-Debt Ratio of -1.09x as of December 2025, meaning its operating cash flow of $-4.62 Million could theoretically repay -1% of its total liabilities ($4.25 Million) in one year. See Gain Therapeutics Inc (GANX) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Gain Therapeutics Inc Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Gain Therapeutics Inc across 8 annual periods. Also explore Gain Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Gain Therapeutics Inc (2018–2025)
Year-by-year debt coverage analysis for Gain Therapeutics Inc. For market capitalisation and broader financial context, see GANX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.34x | $-18.47 Million | $4.25 Million | ▼ -10.0% |
| 2024 | -3.94x | $-18.87 Million | $4.78 Million | ▼ -26.1% |
| 2023 | -3.13x | $-18.87 Million | $6.03 Million | ▼ -11.1% |
| 2022 | -2.81x | $-14.69 Million | $5.22 Million | ▲ +5.1% |
| 2021 | -2.97x | $-12.37 Million | $4.17 Million | ▼ -211.6% |
| 2020 | -0.95x | $-3.24 Million | $3.40 Million | ▲ +43.4% |
| 2019 | -1.68x | $-1.87 Million | $1.11 Million | ▼ -298.5% |
| 2018 | -0.42x | $-744.51K | $1.76 Million | — |